The conditional promise of dual-epitope HER2 antibody-drug conjugates in breast cancer

References

1. 1.↵
   2. Cortazar P,
   3. Zhang L,
   4. Untch M,
   5. Mehta K,
   6. Costantino JP,
   7. Wolmark N, et al.

   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384: 164–72.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   2. Gianni L,
   3. Pienkowski T,
   4. Im YH,
   5. Tseng LM,
   6. Liu MC,
   7. Lluch A, et al.

   5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17: 791–800.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Chen B,
   3. Zheng X,
   4. Wu J,
   5. Chen G,
   6. Yu J,
   7. Xu Y, et al.

   Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025; 24: 279.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Xu D,
   3. Chen ZS,
   4. Peng X,
   5. Lin Z,
   6. Lu H.

   Research progress of antibody–drug conjugates in gynecologic cancer. Holist Integ Oncol. 2024; 3: 42.

   OpenUrl
5. 5.↵
   2. Drago JZ,
   3. Modi S,
   4. Chandarlapaty S.

   Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021; 18: 327–44.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Modi S,
   3. Jacot W,
   4. Yamashita T,
   5. Sohn J,
   6. Vidal M,
   7. Tokunaga E, et al.

   Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022; 387: 9–20.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. von Minckwitz G,
   3. Huang CS,
   4. Mano MS,
   5. Loibl S,
   6. Mamounas EP,
   7. Untch M, et al.

   Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380: 617–28.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Oganesyan V,
   3. Peng L,
   4. Bee JS,
   5. Li J,
   6. Perry SR,
   7. Comer F, et al.

   Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J Biol Chem. 2018; 293: 8439–48.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   2. Cerci B,
   3. Saatci O,
   4. Basik M,
   5. Sahin O.

   Mechanisms of resistance to antibody–drug conjugates in breast cancer. Drug Resist Updat. 2026; 85: 101353.
10. 10.↵
    2. Weisser NE,
    3. Sanches M,
    4. Escobar-Cabrera E,
    5. O’Toole J,
    6. Whalen E,
    7. Chan PWY, et al.

    An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023; 14: 1394.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Xue Q,
    3. Peng J,
    4. Dai W,
    5. Wu Q,
    6. Jiao J,
    7. Hu Y, et al.

    A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy. RSC Chem Biol. 2025; 6: 1284–96.

    OpenUrlPubMed
12. 12.↵
    2. Oh DY,
    3. Bedard PL,
    4. Lee KW,
    5. Han HS,
    6. Kang YK,
    7. Miller WH, et al.

    Abstract B130: Phase 1 study of zanidatamab zovodotin (ZW49): safety profile and recommended dose (RD) in patients with human epidermal growth factor 2 (HER2)-positive solid cancers. Mol Cancer Ther. 2023; 22: B130.

    OpenUrl
13. 13.↵
    2. Pegram MD,
    3. Hamilton EP,
    4. Tan AR,
    5. Storniolo AM,
    6. Balic K,
    7. Rosenbaum AI, et al.

    First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther. 2021; 20: 1442–53.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    2. Park JJ,
    3. Gao B,
    4. Beecroft C,
    5. Wilkinson KJ,
    6. Parsonson A,
    7. Zhang K, et al.

    Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: a first-in-human, dose-escalation, multicenter, open-label, phase I study. J Clin Oncol. 2024; 42: 3038.

    OpenUrl
15. 15.↵
    2. Xu RH,
    3. Wang S,
    4. Ruan DY,
    5. Lin S,
    6. Liu FR,
    7. Wu HX, et al.

    Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: preliminary data from the first-in-human phase 1 trial. J Clin Oncol. 2025; 43: 3003.

    OpenUrl
16. 16.↵
    2. Wang S,
    3. Zhang Q,
    4. Yang J,
    5. Sun T,
    6. Lin S,
    7. Shi Y, et al.

    Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: results from a phase 1b study. J Clin Oncol. 2025; 43: 1090.

    OpenUrl
17. 17.↵
    2. Li JJ,
    3. Zhang WJ,
    4. Zeng XH,
    5. Zhang QY,
    6. Chen L,
    7. Wu J, et al.

    Efficacy and safety of neoadjuvant TQB2102 in locally advanced or early human epidermal growth factor receptor 2-positive breast cancer: a randomized, open-label, multicenter, phase II trial. J Clin Oncol. 2026; 44: 20–30.

    OpenUrlPubMed
18. 18.↵
    2. Harbeck N,
    3. Modi S,
    4. Pusztai L,
    5. Ohno S,
    6. Wu J,
    7. Kim SB, et al.

    Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2026; 37: 166–79.

    OpenUrlPubMed
19. 19.↵
    2. Li JJ,
    3. Wang ZH,
    4. Chen L,
    5. Zhang WJ,
    6. Ma LXX,
    7. Wu J, et al.

    Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial. Ann Oncol. 2025; 36: 651–9.

    OpenUrlPubMed
20. 20.↵
    2. Liu CG,
    3. Gu X,
    4. Qiu F,
    5. Zheng X,
    6. Zhao Y,
    7. Niu N, et al.

    306P Neoadjuvant SHR-A1811 with or without pyrotinib in HER2-positive breast cancer (MUKDEN 07): a multi-cohort, multicenter, phase II clinical trial. Ann Oncol. 2025; 36: S311.

    OpenUrl